JP2021521412A5 - - Google Patents

Info

Publication number
JP2021521412A5
JP2021521412A5 JP2020544212A JP2020544212A JP2021521412A5 JP 2021521412 A5 JP2021521412 A5 JP 2021521412A5 JP 2020544212 A JP2020544212 A JP 2020544212A JP 2020544212 A JP2020544212 A JP 2020544212A JP 2021521412 A5 JP2021521412 A5 JP 2021521412A5
Authority
JP
Japan
Prior art keywords
proteins
stationary phase
phase material
data
purity
Prior art date
Application number
JP2020544212A
Other languages
English (en)
Japanese (ja)
Other versions
JP7332610B2 (ja
JPWO2019165148A5 (https=
JP2021521412A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/019050 external-priority patent/WO2019165148A1/en
Publication of JP2021521412A publication Critical patent/JP2021521412A/ja
Publication of JP2021521412A5 publication Critical patent/JP2021521412A5/ja
Publication of JPWO2019165148A5 publication Critical patent/JPWO2019165148A5/ja
Application granted granted Critical
Publication of JP7332610B2 publication Critical patent/JP7332610B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020544212A 2018-02-21 2019-02-21 タンパク質の精製条件の決定 Active JP7332610B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862633584P 2018-02-21 2018-02-21
US62/633,584 2018-02-21
PCT/US2019/019050 WO2019165148A1 (en) 2018-02-21 2019-02-21 Determining conditions for purification of proteins

Publications (4)

Publication Number Publication Date
JP2021521412A JP2021521412A (ja) 2021-08-26
JP2021521412A5 true JP2021521412A5 (https=) 2022-03-02
JPWO2019165148A5 JPWO2019165148A5 (https=) 2022-03-02
JP7332610B2 JP7332610B2 (ja) 2023-08-23

Family

ID=65763767

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544212A Active JP7332610B2 (ja) 2018-02-21 2019-02-21 タンパク質の精製条件の決定

Country Status (6)

Country Link
US (1) US20200408728A1 (https=)
EP (2) EP3755447B1 (https=)
JP (1) JP7332610B2 (https=)
CA (1) CA3091905C (https=)
ES (1) ES2978413T3 (https=)
WO (1) WO2019165148A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
MX2022013313A (es) * 2020-04-23 2022-11-30 Amgen Inc Seleccion de parametros de cromatografia para la fabricacion de proteinas terapeuticas.
CA3195893A1 (en) * 2020-09-21 2022-03-24 Bayer Healthcare Llc Pathogen clearance system and method
WO2025064403A2 (en) * 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
CN121075496B (zh) * 2025-11-05 2026-03-27 鲁东大学 一种基于特征工程与集成学习的蛋白质盐敏感性预测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010566A1 (en) * 2000-04-11 2002-01-24 Chester Thomas Lee Methods for modeling, predicting, and optimizing high performance liquid chromatography parameters
US20040034477A1 (en) * 2002-08-19 2004-02-19 Mcbrien Michael Methods for modeling chromatographic variables
EP1539321A1 (de) * 2002-09-19 2005-06-15 MERCK PATENT GmbH Verfahren zum auffinden geeigneter chromatographiebedingungen zur trennung biologischer moleküle
DE102006027496B3 (de) * 2006-06-14 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Optimierung chromatographischer Reinigungsverfahren für Biomoleküle
US11460455B2 (en) * 2014-11-12 2022-10-04 Cytiva Sweden Ab Method and system for determining the influence of experimental parameters on a liquid chromatography protocol
GB2539420B (en) * 2015-06-16 2021-01-13 Cytiva Sweden Ab Determination of chromatography conditions

Similar Documents

Publication Publication Date Title
JP2021521412A5 (https=)
Timms et al. Difference gel electrophoresis
Qian et al. Quantitative proteome analysis of human plasma following in vivo lipopolysaccharide administration using 16O/18O labeling and the accurate mass and time tag approach
Lame et al. Quantitation of amyloid beta peptides Aβ1–38, Aβ1–40, and Aβ1–42 in human cerebrospinal fluid by ultra-performance liquid chromatography–tandem mass spectrometry
Millioni et al. High abundance proteins depletion vs low abundance proteins enrichment: comparison of methods to reduce the plasma proteome complexity
JP2020514746A5 (https=)
JP5778547B2 (ja) ヘモグロビンA1c測定における校正方法
Dowling et al. Characterization of contractile proteins from skeletal muscle using gel-based top-down proteomics
Dowling et al. Proteomic profiling of carbonic anhydrase CA3 in skeletal muscle
JP7332610B2 (ja) タンパク質の精製条件の決定
JP2015518169A5 (https=)
Herosimczyk et al. Plasma proteome analysis: 2D geld and chips
Li et al. Screening and identification of specific aptamers for shellfish allergen tropomyosin with capillary electrophoresis-SELEX
Wiederkehr et al. Two-dimensional gel electrophoresis of cerebrospinal fluid proteins from patients with various neurological diseases.
CN104911186B (zh) 一种特异性识别黄曲霉素b1的单链dna寡核苷酸适配子
Diez et al. 2-D fluorescence difference gel electrophoresis (DIGE) in neuroproteomics
JPWO2019165148A5 (https=)
US10376813B2 (en) Determination of chromatography conditions
Salmanowicz et al. Charge-based characterisation of high-molecular-weight glutenin subunits from common wheat by capillary isoelectric focusing
Staunton et al. Proteomic analysis of muscle affected by motor neuron degeneration: the wobbler mouse model of amyotrophic lateral sclerosis
CN105334329B (zh) 钙蛋白酶磷酸化水平的测定方法
EP3341729A1 (en) Method for determining affinity of a biomolecule
Ohlendieck Comparative 3-sample 2D-DIGE analysis of skeletal muscles
Kaliszan et al. QSAR in chromatography: quantitative structure–retention relationships (QSRRs)
Yu et al. Mass Spectrometry‐Based Proteomics Technologies to Define Endogenous Protein‐Protein Interactions and Their Applications to Cancer and Viral Infectious Diseases